EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world data

MammaPrint sagt den Chemotherapie-Nutzen bei HR+HER2- frühem Mammakarzinom voraus: FLEX-Register mit Real-World-Daten

Adam M Brufsky iD, Kent F Hoskins iD, Henry J Conter iD, Pond Kelemen, Mehran Habibi iD, Laila Samian iD, Rakshanda L Rahman iD, Laura Lee, Eduardo C Dias iD, Regina Hampton iD, Beth A Sieling, Cynthia R Osborne iD und 15 weitere

JNCI Cancer Spectrum · 01.09.2025 · 9 (5)

DOI: 10.1093/jncics/pkaf079 ↗

Auf einen Blick

Bei 1002 Patient:innen mit HR+HER2- frühem Mammakarzinom sagte der MammaPrint Index sowohl die DRFI als auch den Nutzen einer Chemotherapie voraus. Der Nutzen war bei höherem Risiko größer.

Fragestellung

Sagt MammaPrint als kontinuierlicher Marker den Nutzen einer adjuvanten Chemotherapie bei HR+HER2- frühem Mammakarzinom voraus?

Methode

Analyse von 1002 Patient:innen aus dem FLEX-Register mit ET allein oder ET+CT; mittlere Nachbeobachtung 5 Jahre; Propensity-Score-Matching nach Menopausenstatus, T-Status und nodalem Status.

Ergebnisse

MPI prognostizierte die 5-Jahres-DRFI in beiden Gruppen (ET: R2 = 0,99; ET+CT: R2 = 0,90; jeweils P < .001). Der durchschnittliche absolute Chemotherapie-Nutzen lag bei 5,6 % in High 1 und 10,9 % in High 2; Low 1,7 %, UltraLow <1,0 %.

Schlussfolgerung der Autor:innen

Die Real-World-Daten aus dem FLEX-Register zeigen laut Autor:innen, dass MPI sowohl die DRFI-Prognose als auch den Chemotherapie-Nutzen bei HR+HER2- frühem Mammakarzinom vorhersagt.

Kernaussagen

  • MPI sagte die 5-Jahres-DRFI in ET- und ET+CT-Gruppen voraus
  • Größerer Chemotherapie-Nutzen bei höherem MPI-Risiko
  • Prämenopausaler Status war mit Chemotherapie-Nutzen assoziiert

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 11.08.2025. Verfasst von Adam M Brufsky und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, United States. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agendia, Inc.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gene expression assays help personalize adjuvant chemotherapy decisions for hormone receptor-positive, HER2-negative (HR+HER2-) early breast cancer (EBC). The 70-gene risk of distant-recurrence signature, MammaPrint, demonstrated clinical utility in guiding chemotherapy de-escalation in genomically low risk patients in the MINDACT trial. This study evaluates MammaPrint as a continuous predictor of chemotherapy benefit in HR+HER2- EBC using real-world data (RWD) from the FLEX Registry.

Methods

The study evaluated 1002 patients treated with endocrine therapy (ET) only or ET with chemotherapy (ET+CT) enrolled in FLEX (NCT03053193) with 5-year median follow-up. Propensity-score matching balanced treatment groups by menopausal status, T-stage, and nodal status. The primary endpoint was distant recurrence-free interval (DRFI). Regression and Cox proportional hazards models assessed chemotherapy benefit across MammaPrint Index (MPI) risk.

Results

Most patients were postmenopausal (70.1%), node-negative (70.0%), and had grade 2 tumors (51.2%). The regression models showed that MPI strongly predicted 5-year DRFI in ET only (R2 = 0.99, P < .001) and ET + CT (R2 = 0.90, P < .001) groups, corresponding to an average absolute chemotherapy benefit of 5.6% in High 1 and 10.9% in High 2. Minimal improvement in DRFI with chemotherapy was observed for Low (1.7%) and UltraLow (<1.0%) risk groups. A multivariate Cox model with an MPI-by-treatment interaction term demonstrated that increasing MPI risk was associated with greater chemotherapy benefit on DRFI (HR = 0.15, P = .047). Chemotherapy benefit was significantly associated with premenopausal status, but not age, T-stage, nodal status, or grade.

Conclusions

These RWD from the FLEX Registry demonstrate that MPI is predictive of both DRFI prognosis and chemotherapy benefit in HR+HER2- EBC. (NCT03053193)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAdultAgedFemaleHumansMiddle AgedAntineoplastic Agents, HormonalBiomarkers, TumorChemotherapy, AdjuvantNeoplasm Recurrence, LocalPostmenopausePropensity ScoreProportional Hazards ModelsErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneRegistries

Substanzen

Antineoplastic Agents, HormonalBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneERBB2 protein, human

Autor:innen und Institutionen

  • Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, United States.
  • College of Medicine, University of Illinois Cancer Center, Chicago, IL, United States.
  • Department of Oncology, William Osler Cancer Centre, Brampton, ON, Canada.
  • Breast Surgical Oncology, Northwell Health, Sleepy Hollow, NY, United States.
  • Breast Surgical Oncology, Northwell Health, Staten Island, NY, United States.
  • Surgical Oncology, Baptist Health MD Anderson Cancer Center, Jacksonville, FL, United States.

ORCID-Profile: Adam M Brufsky, Kent F Hoskins, Henry J Conter, Mehran Habibi, Laila Samian, Rakshanda L Rahman, Eduardo C Dias, Regina Hampton, Cynthia R Osborne, Eric Brown, Jailan A Elayoubi, Priyanka Sharma, Laurie Matt-Amaral, Philip Albaneze, Nicole Chmielewski-Stivers, Andrea Menicucci, William Audeh, Nathalie Johnson

Förderung

  • Agendia, Inc

Zitieren

APA

Brufsky, A. M., Hoskins, K. F., Conter, H. J., Kelemen, P., Habibi, M., Samian, L., Rahman, R. L., Lee, L., Dias, E. C., Hampton, R., Sieling, B. A., Osborne, C. R., Brown, E., Elayoubi, J. A., Sharma, P., Ramadurai, J., Matt-Amaral, L., Santillan, A. A., Davis, S., …, & O'Shaughnessy, J. (2025). MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world data. JNCI Cancer Spectrum, 9(5). https://doi.org/10.1093/jncics/pkaf079

Vancouver

Brufsky AM, Hoskins KF, Conter HJ, Kelemen P, Habibi M, Samian L, et al. MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world data. JNCI Cancer Spectrum. 2025;9(5). doi:10.1093/jncics/pkaf079

BibTeX
@article{Brufsky2025,
  author = {Brufsky, Adam M and Hoskins, Kent F and Conter, Henry J and Kelemen, Pond and Habibi, Mehran and Samian, Laila and Rahman, Rakshanda L and Lee, Laura and Dias, Eduardo C and Hampton, Regina and Sieling, Beth A and Osborne, Cynthia R and Brown, Eric and Elayoubi, Jailan A and Sharma, Priyanka and Ramadurai, Jayanthi and Matt-Amaral, Laurie and Santillan, Alfredo A and Davis, Sasha and Albaneze, Philip and Ramaswamy, Harshini and Chmielewski-Stivers, Nicole and Menicucci, Andrea and Audeh, William and Whitworth, Pat and Johnson, Nathalie and O'Shaughnessy, Joyce},
  title = {MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world data},
  journal = {JNCI Cancer Spectrum},
  year = {2025},
  volume = {9},
  number = {5},
  doi = {10.1093/jncics/pkaf079}
}
Kostenlos starten →